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Abstract
Pneumococcal surface proteins (PSPs) elicit antibody responses in infants and young children exposed to Streptococcus pneumoniae. These
seroresponses could contribute to the aetiological diagnosis of pneumococcal disease, e.g. during the clinical development of novel PSP-
based vaccines. In this study, we assessed the kinetics of antibody responses to three highly conserved and immunogenic PSPs (pneumococ-
cal histidine triad D (PhtD), pneumococcal choline-binding protein A (PcpA), and serine proteinase precursor A (PrtA)) in 106 children
(median age, 21.3 months; males, 58.5%) admitted for pneumococcal bacteraemia. Anti-PhtD, anti-PcpA and anti-PrtA antibodies were
measured by ELISA, and compared in 61 pairs of acute (£7 days) and convalescent (>14 days of admission) serum samples. Acute serum ti-
tres were similar to those observed in healthy children, and were unaffected by the acid dissociation of circulating immune complexes.
Despite proven bacteraemia, seroresponses (‡2-fold increase in anti-PSP antibody concentrations) were only identified in 31 of 61 children
(50.8%), directed against PrtA (n = 23, 37.7%), PcpA (n = 19, 31.1%), and PhtD (n = 16, 26.2%), or several PSPs (two PSPs, n = 13, 21.3%;
three PSPs, n = 7, 11.5%). Certain seroresponses were very strong (maximal fold-increases: PhtD, 26; PcpA, 72; PrtA, 12). However, anti-
PSP antibody concentrations failed to increase in the convalescent sera of 30 of 61 (49.2%) bacteraemic children, and even declined (‡2 fold)
in 13 of 61 (21.3%), mostly infants aged <6 months (8/13, 61.5%), possibly through consumption of maternal antibodies. Thus, pneumococ-
cal bacteraemia may fail to elicit antibody responses, and may even have an antibody-depleting effect in infants. This novel observation iden-
tifies an important limitation of serology-based studies for the identification of bacteraemic children.
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Streptococcus pneumoniae is a common pathogen causing invasive
diseases, and an important cause of paediatric mortality [1–3].
Pneumococcal bacteraemia continues to be of concern, because
of its inherent risk of progressing to sepsis or meningitis in
young children [4]. Its diagnosis is often challenging, as blood cul-
tures may be unavailable or negative [4]. Although conjugated
pneumococcal vaccines have decreased its incidence [1,4–8],
there are concerns related to the emergence of non-vaccine
S. pneumoniae serotypes [3]. New strategies are thus being
investigated to develop vaccines that include pneumococcal sur-
face proteins (PSPs) as antigens for ‘universal’ pneumococcal
vaccines [9,10]. Specific antibodies against PSPs are produced
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naturally [11], and infants may already develop anti-PSP antibod-
ies in response to S. pneumoniae colonization (Hagerman A, Pos-
fay-Barbe KM, Grillet S, Ochs MM, Brookes RH, Greenberg D,
Givon-Lavi N, Dagan R, Siegrist C-A, unpublished data) or infec-
tion. As some of these PSPs are conserved in >97% of S. pneu-
moniae serotypes [12], PSP-specific seroresponses could be
used for the aetiological confirmation of suspected S. pneumo-
niae infections, e.g. during vaccine studies. Three surface-
exposed PSPs were selected primarily on the basis of their
availability, their putative role(s) in bacterial pathogenesis, and
their conservation across pneumococcal strains (>97%) [12].
Pneumococcal histidine triad D (PhtD) is thought to be
involved in the invasion process [13]. Anti-PhtD antibodies
have been detected in convalescent-phase sera in children with
pneumococcal bacteraemia, confirming that this protein is
exposed and recognized by the immune system during pneu-
mococcal disease [13,14]. Pneumococcal choline-binding pro-
tein A (PcpA) is a choline-binding protein that is suggested to
play a role in bacterial adherence to the epithelium in the
lower respiratory tract. PcpA is distinct from other pneumo-
coccal choline-binding proteins (PspC and CbpA) [13,15,16].
Some studies have shown that the manganese concentration
directly affects the surface expression of PcpA, its expression
probably being increased when bacteria infect low-manganese
sites, such as lungs and blood [15]. Serine proteinase precur-
sor A (PrtA) contributes to pneumococcal virulence [11], and
its expression is also regulated by manganese concentrations.
The aim of this study was to define the kinetics of anti-
body responses to three immunogenic and conserved PSPs
(PhtD, PcpA, and PrtA) in children with proven pneumococ-
cal bacteraemia. We compared two populations, living in the
same region with different socio-economic conditions and




Children <15 years of age were enrolled prospectively. They
were admitted to the Soroka University Medical Centre,
Israel between 1996 and 2007 with proven bacteraemia
(positive blood culture for S. pneumoniae), and provided
paired acute/convalescent blood samples after written
informed consent had been obtained. None had been immu-
nized against S. pneumoniae. Serum samples were stored at
)70C until analysis. The study was approved by the Soroka
University Medical Centre Ethics Committee. Acute samples
were obtained within 7 days of admission, and convalescent
samples were obtained at least 2 weeks after admission.
Setting
In southern Israel, the Jewish population is mainly urban,
whereas the Bedouin population is gradually moving away
from its nomadic lifestyle [17]. Children of the two popula-
tions do not frequent the same day-care facilities or schools,
and do not have a common social life, but all are entitled to
free medical care. In 2004, the crude birth rate was 55.3 vs.
21.0 births per 1000 persons in the Bedouin and Jewish pop-
ulations, respectively [18], and the mean ± standard devia-
tion family size among the Bedouin population was
8.2 ± 0.9 persons as compared with 3.2 ± 0.1 persons
among the Jewish population [19]. Hospitalization rates for
respiratory and other infectious diseases were higher among
Bedouins [20]. During the study period, the seven-valent
pneumococcal conjugate vaccine had not yet been intro-
duced in Israel, and <3% of the population had participated
in clinical trials with one of the experimental pneumococcal
conjugate vaccines.
PhtD, a truncated version of PcpA and a truncated histi-
dine-tagged version of PrtA were recombinantly expressed
in and purified from Escherichia coli. The specificity of PhtD
and PcpA antigen-specific ELISA was demonstrated by com-
plete loss of binding of human antibody sera by competitive
inhibition with specific antigens, and not with other PSPs as
control antigens.
Serological analyses
Paired acute and convalescent serum samples were tested in
the same run by indirect ELISA, with purified proteins being
used to coat Immulon (Thermo Labsystem, Helsinki, Finland)
plates, anti-IgG antibody (Cappel Laboratory, Cochranville,
PA, USA), and ABTS substrate, as previously described [12].
Eight serial dilutions (two-fold) of serum samples were per-
formed to allow precise quantification of antibody titres. A
common reference human antibody serum was used in each
assay. Its antibody concentration in ELISA Units was defined
by the reciprocal of its dilution at OD = 1.0. Assay results
were expressed in EU/mL by interpolation with the refer-
ence serum, allowing precise quantification. A cut-off of
5 EU/mL was experimentally identified as allowing the reli-
able detection of serum concentrations. Anti-PSP antibody
concentrations below 5 EU/mL were given a titre of 2.5 EU/
mL. A significant rise in antibody titres was conservatively
predefined as a minimal two-fold (100%) increase between
the acute-phase and convalescent-phase samples.
To determine whether low antibody concentrations
reflected the presence of circulating immune complexes, the
sera of 35 children aged ‡12 months were acid-treated by
incubation in a 0.2 M glycine-HCl (pH 2.5) dissociation buffer
for 20 min at room temperature [21]. A Tris-HCl 1 M
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(pH 9.5) buffer was added to stop the dissociation reaction,
immediately prior to the parallel quantification of serum anti-
bodies in dissociated/native sera to identify samples with
enhanced ELISA signals.
Statistical analyses
Statistical analysis was carried out with SPSS (PASW Statis-
tics 18.0.0; IBM Corporation, Somers, NY, USA). Standard
descriptive statistics were used to describe socio-demo-
graphic characteristics. Categorical data were compared by
the use of chi-square tests or Fisher’s exact tests when
appropriate. Serological findings among groups were com-
pared by using Student’s t-test, linear regression, or the
Mann–Whitney U-test, according to the type of independent
variable. A multivariate linear regression analysis model was
used to assess goodness-of-fit and calculate adjusted ORs
and 95% CIs, for variables that had p-value of <0.25 in uni-
variate analyses. For all statistical tests, differences were con-
sidered significant at p <0.05 or when the 95% CI did not
include 1.0.
Results
One hundred and six children aged 7 days to 15 years were
enrolled. They were divided in five age groups, each including
at least 17 children (Table 1). Bacteraemic children were
more frequently from the Bedouin (70.8%) community, and
were more likely to be boys (58.5%).
Acute serum samples were available for 95 children. Anti-
bodies against all three PSPs were detectable in all age
groups (Table 2a), ranging from very low to high levels. The
lowest anti-PSP antibody concentrations were observed in
infants, and the highest in children aged >24 months (PcpA)
or 47 months (PhtD and PrtA). In contrast to healthy
children from the same communities (Hagerman A. et al.,
unpublished data), anti-PSP antibody concentrations were
not higher in Bedouin children overall. The dissociation of
circulating immune complexes by acid treatment did not
increase serum antibody concentrations (mean ratios in acid-
treated/naı¨ve samples: PhtD, 0.96 ± 0.18; PcpA, 0.99 ± 0.09;
PrtA, 0.85 ± 0.17).
Convalescent serum samples were available for 72 chil-
dren. Anti-PSP antibodies were detected in all children, again
at similar concentrations in the two ethnic groups
(Table 2b). Seroresponses to pneumococcal bacteraemia
were measured after a median interval of 30.6 days in 61
children with available paired acute/convalescent samples
(Table 3). This sampling interval did not affect antibody
responses (data not shown). The mean convalescent/acute
geometric mean concentration ratios were PSP-specific
(PhtD, 2.32; PcpA, 4.62; PrtA, 2.28) (Fig. 1). The maximal
ratio was high for each PSP (anti-PhtD, 26-fold; anti-PcpA,
72-fold; anti-PrtA, 12-fold), confirming the immunogenicity of
these three PSPs. However, seroresponses (‡2-fold increase)
were observed in only 31 of 61 (50.8%) children, regardless
of age (Fig. 2). Antibodies were directed against PrtA, PcpA
and PhtD in, respectively, 23 (37.7%), 19 (31.1%) and 16
(26.2%) children. Seroresponses were observed against two
PSPs in 13 (21.3%) children and against all three PSPs in
seven (11.5%) children.
In three bacteraemic children, a >2-fold decline in the
concentration of antibody against a specific PSP was
observed, in parallel with a ‡2-fold increase in the concen-
tration of antibody against another PSP. Lower anti-PSP anti-
body concentrations in convalescent than in acute samples
were observed in 13 of 61 (21.3%) children, mostly in infants
younger than 6 months (8/13, 61.5%). This decline in anti-
PSP antibody concentrations affected two or three PSPs in
seven of 13 (53.8%) children, confirming their biological sig-
nificance.
Remarkably, 30 of 61 (49.2%) children failed to raise even a
modest (‡2-fold) seroresponse to any of the three immuno-
genic and conserved PSPs tested. Among these non-respond-
ers, 20 (66.7%) failed to increase their antibody concentrations
above baseline values, whereas a decline in anti-PSP antibody
TABLE 1. Characteristics of 106









Age group distribution in months All 106 (21.3, 43.9) 75 (70.8) 31 (29.2)
0–5b 21 (3, 2.9) 18 (24) 3 (9.7)
6–11b 17 (9, 4.4) 13 (17.3) 4 (12.9)
12–23b 20 (18.6, 6.2) 14 (18.7) 6 (19.35)
24–47b 20 (34.8, 15) 14 (18.7) 6 (19.35)
>47b 28 (90.5, 72) 16 (21.3) 12 (38.7)
Male gender, n (%) 62 (58.5) 46 (61.3) 16 (51.6)
IQR, interquartile range.
aAll comparisons not statistically significant.
bPercentage within ethnicity.
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concentration between acute and convalescent samples was
observed in ten (33.3%) children. There was no significant
influence of age or ethnicity on seroresponses.
Discussion
This study identifies a major hurdle to the potential use of
seroresponses for the aetiological diagnosis of S. pneumoniae
pneumococcal bacteraemia: a bacteriologically proven pneu-
mococcal infection may fail to elicit antibody responses to
highly conserved PSPs, both in infants and in toddlers.
Although the pattern and the magnitude of seroresponses
differed between PhtD, PcpA, and PrtA, they followed similar
trends.
Whether children admitted for pneumococcal bacteraemia
had lower anti-PSP antibody titres than healthy children in
the same age group and community is as yet unknown.
Indeed, certain anti-PSP antibodies are protective against
murine invasive disease [10,14,15,22], and anti-PSP serore-
sponses could contribute to the decline in the incidence of
pneumococcal invasive disease after the second year of life
[23]. In support of this hypothesis, Obaro et al. [24] showed
lower anti-PSP antibody titres in colonized than in uncolon-
ized infants, raising the possibility that some anti-PSP anti-
bodies may protect against S. pneumoniae carriage and
therefore against invasive disease. Our group previously
reported three-fold lower concentrations of anti-PcpA
antibodies in the acute sera of children diagnosed with
community-acquired pneumonia of presumed pneumococcal
TABLE 2. Anti-pneumococcal surface protein antibody geometric mean concentrations (GMC) of children with acute and con-
valescent blood samples following bacteriologically proven pneumococcal bacteraemia, by age group and ethnicity
Age group (months) n
GMC (EU/mL)
All (95% CI) Bedouin children Jewish children p-value
(a) Acute blood samples
PhtD
All 95 37.6 (26.2–54) 33.4 55.5 NS
0–5 19 16.5 (7.4–36.3) 14.7 42.7 NS
6–11 15 11.2 (4.8–26) 10.7 13.2 NS
12–23 18 20.8 (9.5–45.7) 33.3 4.1 0.049
24–47 17 65.5 (33.3–128.7) 64 70.7 NS
>47 26 145.5 (94.1–225.2) 119.4 183.3 NS
PcpA
All 95 316.3 (227.5–439.8) 293.6 394.6 NS
0–5 19 181.8 (96.2–343.7) 180.3 195 NS
6–11 15 131 (41.8–410.2) 121.5 176.9 NS
12–23 18 148.1 (75.7–289.6) 170.7 90.1 NS
24–47 17 707.4 (399.2–1253.4) 1025 211.9 0.031
>47 26 788.2 (535–1161) 596.3 1091.3 NS
PrtA
All 95 70.3 (47.3–104.4) 70.8 73.2 NS
0–5 19 41.8 (20.5–85.2) 38.2 89.4 NS
6–11 15 13.5 (6–30.4) 12.9 16.3 NS
12–23 18 22.6 (10.6–48.4) 39.2 3.3 0.009
24–47 17 139.7 (66.1–295.4) 178.9 62.6 NS
>47 26 372.2 (219.5–631) 442.2 304.4 NS
(b) Convalescent blood samples
PhtD
All 72 56.5 (36.1–88.3) 45.6 103.1 NS
0–5 15 17.2 (7.9–37.5) 17.7 15.3 NS
6–11 12 15.8 (4.7–52.6) 15.3 18.7 NS
12–23 14 45.5 (20–103.6) 39.6 64.3 NS
24–47 8 123.8 (24.2–635) 97 186 NS
>47 23 207.2 (131.5–326.5) 167.6 288.1 NS
PcpA
All 72 438.7 (287.3–669.6) 452.7 415.4 NS
0–5 15 134.1 (50.5–356.2) 181.6 39.9 NS
6–11 12 402.9 (112.8–1438.8) 363.9 670.5 NS
12–23 14 296.9 (123.3–714.9) 356.1 188.4 NS
24–47 8 771.3 (215.4–2761.4) 1529.7 246.3 NS
>47 23 1035.3 (657.5–1630.1) 860.8 1379.6 NS
PrtA
All 72 99.8 (62.1–160.5) 112.4 85.3 NS
0–5 15 29.5 (15.2–57.3) 32.1 21.1 NS
6–11 12 19.4 (7.5–50.1) 18.5 24.5 NS
12–23 14 62.4 (23.8–163.7) 114 13.8 NS
24–47 8 342.2 (104.2–1123.4) 346.9 334.5 NS
>47 23 450.6 (231.6–876.6) 648.9 255.4 NS
NS, not significant; PcpA, pneumococcal choline-binding protein A; PhtD, pneumococcal histidine triad D; PrtA, serine proteinase precursor A.
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origin in Geneva, Switzerland [12], and regression analyses
identified a low acute anti-PcpA antibody concentration as
an independent predictor (p 0.002) of community-acquired
pneumonia of presumed pneumococcal origin. This pattern
of lower anti-PcpA antibody concentrations at admission was
not observed in Israeli children with pneumococcal bactera-
emia: anti-PSP antibody concentrations in bacteraemic chil-
dren were similar to or higher than those in healthy children
in both communities (Hagerman A. et al., unpublished data).
This is in accordance with a report including 25 adult
patients with pneumococcal meningitis [11]. An exception
was observed between 12 and 23 months, anti-PSP antibody
titres being significantly lower in bacteraemic than healthy
children (geometric mean concentrations: PhtD, 72.3 vs.
20.8, p 0.023; PcpA, 813.7 vs. 148.1, p 0.004; PrtA, 95.2 vs.
22.6, p 0.022). Whether low anti-PSP antibody concentra-
tions predispose toddlers to bacteraemic infections should
thus be assessed in longitudinal prospective cohort studies.
Approximately half of the bacteraemic children raised sig-
nificant seroresponses in the weeks following the initial
(acute) visit. These anti-PSP responses were occasionally
very strong, as reported in 14 adults [25]. They were direc-
ted against one (26–38%), two (21.3%) or even three
(11.5%) of the three PSPs tested. This confirmed both their
surface expression by the invading pathogens and their
strong immunogenicity. The strongest seroresponses were
raised to PcpA (72-fold) and PrtA (12-fold). This may reflect
the triggering of PcpA/PrtA expression by the lower-manga-
nese (Mn2+) environment during bacteraemia than in the
nasopharynx [15,26].
Unexpectedly, such seroresponses were absent in half of
the children with confirmed pneumococcal bacteraemia.
Several hypotheses may explain this high frequency of non-
responders. Anti-PSP antibodies produced against a single
pathogenic protein may not recognize all allelic variants
[10], although these PSPs are highly conserved [12]. Never-
theless, genes may be absent or not expressed in 1–3% of
TABLE 3. Anti-pneumococcal surface protein antibody geo-
metric mean concentrations (GMCs) of 61 children with
paired acute and convalescent blood samples following bac-
teriologically proven pneumococcal bacteraemia, by age
group
Age group (months) n
Mean GMC (EU/mL)
Acute sample Convalescent sample
PhtD
All 61a 137.3 217.9
0–5 13 50.08 62.46
6–11 9 46.89 56.44
12–23 12 47.25 85.75
24–47 5 118.4 608.8
>47 21 286.62 364.33
PcpA
All 61a 732.2 1370.5
0–5 13 389.77 879.62
6–11 9 916.44 1673.44
12–23 12 269.17 690.25
24–47 5 1020 1631.8
>47 21 1077.05 1902.14
PrtA
All 61a 276.2 493.9
0–5 13 87.23 56.54
6–11 9 70.22 70.56
12–23 15 76.75 218.67
24–47 5 220.6 482.4
>47 21 606.62 1044
PcpA, pneumococcal choline-binding protein A; PhtD, pneumococcal histidine
triad D; PrtA, serine proteinase precursor A.





















0–5 months 6–11 months 12–23 months 24–47 months ≥ 48 months
PhtD ratio PcpA ratio PrtA ratio
FIG. 1. Fold-increase of anti-pneumococcal surface protein (PSP)
antibody concentrations in bacteraemic children. The ratio of conva-
lescent to acute anti-PSP antibody geometric mean concentration
(GMC) is illustrated for each PSP and age group. PcpA, pneumococ-
cal choline-binding protein A; PhtD, pneumococcal histidine triad D;











FIG. 2. Proportion of seroresponders among bacteraemic children
by age category. The proportion of bacteraemic children with a ‡2-
fold increase in anti-PSP antibody concentration is illustrated for
each pneumococcal surface protein and age group. PcpA, pneumo-
coccal choline-binding protein A; PhtD, pneumococcal histidine
triad D; PrtA, serine proteinase precursor A.
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the strains. However, this study was performed over a per-
iod of several years, and it therefore seems highly unlikely
that a large clonal expansion of PSP-negative strains can
explain these results. Finally, the high diversity of serotypes
found among these children also makes it unlikely that cer-
tain PSPs were ‘hidden’ by, for example, the polysaccharidic
capsule. Young infants may not raise seroresponses,
because of their immune immaturity and/or the inhibitory
influence of maternal antibodies [27], and, indeed, infants
aged <6 months were over-represented among non-
responders. It may be difficult for older children with high
pre-existing antibody concentrations, or whose antibody
responses were initiated a few days prior to admission, to
further increase their antibody levels ‡2-fold. Specifically
regarding the children with the highest acute concentrations
of antibodies against these three PSPs, this group of chil-
dren was less likely to have a ‡2-fold antibody increase
over time, although this was only significant for PhtD (data
not shown). However, the concentrations of antibodies
against at least one of the three PSP tested were frequently
low, which should have allowed the detection of serore-
sponses. The presence of circulating immune complexes
may reduce the concentrations of antibodies against pneu-
mococcal polysaccharides, which may also affect anti-PSP
antibodies. Lower convalescent than acute anti-PSP antibody
titres were, indeed, occasionally observed, mostly in infants
younger than 6 months of age, in whom baseline anti-PSP
antibodies essentially reflect passively transmitted maternal
antibodies [13], and in whom convalescent titres may fail to
increase, as a result of immune immaturity and/or the inhib-
itory influence of maternal antibodies (reviewed in [27]).
However, the dissociation of immune complexes remained
without influence on anti-PSP antibody concentrations,
which is likely to reflect the greater abundance of circulat-
ing polysaccharides than of specific PSPs. Seroresponses
may take more than 2–4 weeks to reach significant levels,
and may thus have been missed by the timing (mean,
30.6 days) of our convalescent blood sampling. However,
we observed no increase in anti-PSP seroresponses with
time after admission, and infection-induced antibody con-
centrations tend to decrease during the late convalescent
phase [11]. We cannot exclude the possibility that adding
many more PSPs would increase the likelihood of detection
of significant seroresponses. As an alternative hypothesis,
the pneumococcal bacteraemia may be too sudden to trig-
ger significant seroresponses and/or elicit some type of
transient ‘immune paralysis’. This would be reminiscent of
the observation that invasive pneumococcal disease [28] or
even nasopharyngeal carriage [29] can result in hyporespon-
siveness to the infecting serotype following subsequent
immunization with a glycoconjugate vaccine [28], an as yet
unexplained phenomenon.
Our study has limitations. We assessed only IgG antibod-
ies, and cannot exclude the possibility that IgM or IgA pat-
terns would be distinct. Although anti-PSP IgG responses
were compared with those of healthy children of the same
community measured during the same period in a parallel
study, we could not match bacteraemic cases and controls
to formally demonstrate similar anti-PSP antibodies at time
of admission in healthy and bacteraemic children. We can
also not exclude the possibility that antibody responses were
initiated a few days before the diagnosis of the bacteraemic
episode, as a result of recent pneumococcal colonization
[30], or that seroresponses would have been detected at
subsequent time-points.
In conclusion, pneumococcal bacteraemia may be associ-
ated with strong anti-PSP seroresponses, but may fail to
increase anti-PSP antibody concentrations in half of the
patients, or even have an antibody-depleting effect in young
infants. This identifies an important limitation to the use of
seroresponses for the identification of bacteraemic children
during clinical trials and vaccine studies.
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